<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65326">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255435</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 408-C-1402</org_study_id>
    <nct_id>NCT02255435</nct_id>
  </id_info>
  <brief_title>RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe</brief_title>
  <official_title>A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Friedreich's Ataxia Research Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Friedreich's ataxia is an autosomal recessive cerebellar ataxia caused by triplet-repeat
      expansions. The causative mutation is a trinucleotide (GAA) repeat expansion in the first
      intron of the frataxin gene, leading to impaired transcription of frataxin. The pathological
      consequences of frataxin deficiency include a severe disruption of iron-sulfur cluster
      biosynthesis, mitochondrial iron overload coupled to cellular iron dysregulation, and an
      increased sensitivity to oxidative stress.

      A hallmark of Friedreich's ataxia is impairment of antioxidative defense mechanisms, which
      play a major role in disease progression. Studies have demonstrated that nuclear factor
      erythroid-derived 2-related factor 2 (Nrf2) signaling is grossly impaired in patients with
      Friedreich's ataxia. Therefore, the ability of omaveloxolone (RTA 408) to activate Nrf2 and
      induce antioxidant target genes is hypothesized to be therapeutic in patients with
      Friedreich's ataxia.

      This 2-part study will evaluate the efficacy, safety, and pharmacodynamics of omaveloxolone
      (RTA 408) in the treatment of patients with Friedreich's ataxia.

      Part 1: The first part of this study will be a randomized, placebo-controlled, double-blind,
      dose-escalation study to evaluate the safety of omaveloxolone (RTA 408) at various doses in
      patients with Friedreich's ataxia.

      Part 2: The second part of this study is a randomized, placebo-controlled, double-blind,
      parallel study to evaluate the safety, efficacy, and pharmacodynamics of up to 2 dose levels
      of omaveloxolone (RTA 408) in patients with Friedreich's ataxia. Eligible patients in Part 2
      will be randomized 1:1:1 to receive omaveloxolone (RTA 408) (at one of 2 doses chosen from
      Part 1), or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the change of peak workload (in watts/kg) during exercise testing</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the change in the modified Friedreich's ataxia rating scale (FARS)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Friedreich Ataxia</condition>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 2.5 and 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally one daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 10 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules TBD mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, TBD mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaveloxolone Capsules 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>omaveloxolone (RTA 408) Capsules, 300 mg taken orally once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 2.5 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 2.5 and 5 mg</arm_group_label>
    <other_name>RTA 408 Capsules 2.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 5 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 2.5 and 5 mg</arm_group_label>
    <other_name>RTA 408 capsules, 5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 10 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 10 mg</arm_group_label>
    <other_name>RTA 408 capsules, 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 20 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 20 mg</arm_group_label>
    <other_name>RTA 408 capsules, 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, TBD mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules TBD mg</arm_group_label>
    <other_name>RTA 408 capsules, TBD mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 40 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 40 mg</arm_group_label>
    <other_name>RTA 408 capsules, 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 80 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 80 mg</arm_group_label>
    <other_name>RTA 408 capsules, 48 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 160 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 160 mg</arm_group_label>
    <other_name>RTA 408 capsules, 160 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone Capsules, 300 mg</intervention_name>
    <arm_group_label>Omaveloxolone Capsules 300 mg</arm_group_label>
    <other_name>RTA 408 capsules, 300 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have genetically confirmed Friedreich's ataxia

          2. Have a modified FARS score ≥10 and ≤80

          3. Be male or female and ≥16 years of age and ≤40 years of age

          4. Have no changes to exercise regimen within 30 days prior to Study Day 1 and be
             willing to remain on the same exercise regimen during the 16-week study period

          5. Have the ability to complete maximal exercise testing

          6. Be able to swallow capsules

        Exclusion Criteria:

          1. Have uncontrolled diabetes (HbA1c &gt;11.0%)

          2. Have B-type natriuretic peptide value &gt;200 pg/mL

          3. Have a history of clinically significant left-sided heart disease and/or clinically
             significant cardiac disease

          4. Have known active fungal, bacterial, and/or viral infection, including human
             immunodeficiency virus or hepatitis virus (B or C)

          5. Have known or suspected active drug or alcohol abuse

          6. Have clinically significant abnormalities of clinical hematology or biochemistry,
             including but not limited to elevations greater than 1.5 times the upper limit of
             normal of aspartate aminotransferase, alanine aminotransferase or creatinine

          7. Have any abnormal laboratory test value or serious pre-existing medical condition
             that, in the opinion of the investigator, would put the patient at risk by study
             enrollment

          8. Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to
             take any of these drugs during the time of study participation:

               1. Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide,
                  midazolam, sildenafil)

               2. Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)

          9. Have participated in any other interventional clinical study within 30 days prior to
             Study Day 1

         10. Have a cognitive impairment that may preclude ability to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Fisher</last_name>
      <phone>310-206-8153</phone>
      <email>adfisher@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Susan Perlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida - Neurology</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aika Konn</last_name>
      <phone>352-273-6003</phone>
      <email>aika.konn@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>SH Subramony, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USF Ataxia Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Allison</last_name>
      <phone>813-974-5909</phone>
      <email>kalliso1@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Theresa Zesiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital - Neurology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky McMurray, RN</last_name>
      <phone>404-712-7013</phone>
      <email>rebecca.s.mcmurray@emory.edu</email>
    </contact>
    <investigator>
      <last_name>George Wilmot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Neurology</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louisa Mezache</last_name>
      <phone>614-685-3030</phone>
      <email>louisa.mezache@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Chad Hoyle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Seyer</last_name>
      <phone>267-426-9738</phone>
      <email>seyerl@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>David Lynch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneieve Tai</last_name>
      <phone>61 3 8341 6374</phone>
      <email>geneieve.tai@mcri.edu.au</email>
    </contact>
    <investigator>
      <last_name>Martin Delatycki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SN Sigrid Zimmermann</last_name>
      <email>sigrid.zimmermann@tirol-kliniken.at</email>
    </contact>
    <investigator>
      <last_name>Sylvia Boesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College of London</name>
      <address>
        <city>London</city>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paola Giunti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 14, 2016</lastchanged_date>
  <firstreceived_date>September 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RTA 408</keyword>
  <keyword>RTA 408 Capsules</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Mitochondrial dysfunction</keyword>
  <keyword>omaveloxolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
